Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:MEK_inhibitor |
| gptkbp:administeredBy |
oral route
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
|
| gptkbp:ATCCode |
L01EE03
|
| gptkbp:brand |
gptkb:Mektovi
|
| gptkbp:CASNumber |
606143-52-6
|
| gptkbp:chemicalFormula |
C17H15BrF2N4O3
|
| gptkbp:compatibleWith |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:contraindication |
pregnancy
lactation |
| gptkbp:developedBy |
gptkb:Array_BioPharma
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
inhibits MEK1/2 enzymes
|
| gptkbp:molecularWeight |
415.2 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1873475
50908541 |
| gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue rash increased creatine phosphokinase |
| gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:UNII |
Q1ZXA2J1XK
|
| gptkbp:usedFor |
treatment of melanoma
treatment of colorectal cancer treatment of non-small cell lung cancer |
| gptkbp:bfsParent |
gptkb:MAP2K1_gene
gptkb:MEK1/2 |
| gptkbp:bfsLayer |
7
|
| http://www.w3.org/2000/01/rdf-schema#label |
Binimetinib
|